Furthermore, one would expect the targeting of CD11b/CD18 and CD11c/CD18 to be associated with a risk of infection due to the inhibition of normal monocytes [242], and this may become particularly important for patients receiving AML therapy with hematological toxicity [3]. This evidence concerns the gene ITGAM and acute myeloid leukemia.